Vicore Pharma Strengthens Executive Ranks as Buloxibutid Nears Key Milestones

Vicore Pharma Holding AB ( (SE:VICO) ) has issued an update.

Vicore Pharma, a clinical-stage biopharma group specializing in angiotensin II type 2 receptor agonists for respiratory and fibrotic diseases, is advancing its lead IPF candidate buloxibutid through a global Phase 2b ASPIRE study and preparing its manufacturing and commercial infrastructure. The Nasdaq Stockholm-listed company is positioning itself as a leader in disease-modifying therapies for conditions such as idiopathic pulmonary fibrosis, supported by U.S. regulatory designations that could accelerate development and market access.

The company has promoted Bernt van den Blink to chief medical officer, Helen Barker to chief technology officer and Jimmie Hofman to chief business officer, consolidating leadership across clinical, manufacturing and business development functions. The reshaped executive team, alongside outgoing CMO Bertil Lindmark in a senior advisory role, is intended to drive buloxibutid’s late-stage development, scale operations for potential commercialization and secure strategic partnerships ahead of key clinical and corporate milestones.

Van den Blink, a pulmonologist with extensive experience in interstitial lung diseases, will oversee clinical development and expansion of Vicore’s next-generation AT2 receptor agonist pipeline. Barker will steer CMC and manufacturing strategy to ensure clinical supply, regulatory readiness and commercial preparation, while Hofman will focus on deal-making and partnering, leveraging his prior track record of large biopharma collaborations to support Vicore’s growth trajectory.

The most recent analyst rating on (SE:VICO) stock is a Sell with a SEK9.50 price target. To see the full list of analyst forecasts on Vicore Pharma Holding AB stock, see the SE:VICO Stock Forecast page.

More about Vicore Pharma Holding AB

Vicore Pharma is a Stockholm-listed clinical-stage biopharmaceutical company focused on respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis. Its lead asset, buloxibutid, is a first-in-class oral angiotensin II type 2 receptor agonist that has U.S. FDA Orphan Drug and Fast Track designations and is being evaluated in the global 52-week Phase 2b ASPIRE trial in IPF.

Average Trading Volume: 631,553

Technical Sentiment Signal: Sell

Current Market Cap: SEK2.87B

Learn more about VICO stock on TipRanks’ Stock Analysis page.